Recent Updates
Recently added Catalysts

BIIB015

Phase 1

Solid Tumors | Small molecule | Oncology |Biogen Inc.|Last Updated: Sep 16, 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment55

FDA Designations

No designations recorded

Clinical trial landscape

BIIB015 · 1 trial · 1 indication

Phase 1 1
NCT00674947A Phase I Study of BIIB015 in Relapsed/Refractory Solid TumorsSolid Tumors
COMPLETED55 Analytics
PHASE1COMPLETED
A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors
Solid Tumors
NCT0067494755
Unlock trial analytics

Study Endpoints

Primary Endpoints

To evaluate safety
ongoing
To determine the maximum-tolerated dose (MTD)
ongoing

Secondary Endpoints

To evaluate pharmacokinetics (PK)
ongoing
To evaluate clinical activity
ongoing
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
BIIB015DRUGIV infusion once every 3 weeks until disease progression or unacceptable toxicity
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria * Age 18 years or older at the time of informed consent. * Solid tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic therapy and for which no standard therapy exists. * ECOG Performance Status \</= 2. Exclusion Criteria * History of keratoconjunctivi...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 9 trials (matched to "Solid Tumors")

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
AstraZeneca PLCAZN1 - Trastuzumab deruxtecan
Unlock Competitive Intelligence

Frequently asked questions about BIIB015

What is BIIB015 used for?

BIIB015 is an investigational small molecule being developed by Biogen for the treatment of solid tumors. It was studied in a Phase 1 clinical trial in patients with relapsed or refractory solid tumors. The drug is not approved and remains in clinical development.

What does BIIB015 target?

The molecular target of BIIB015 has not been disclosed. It is a small molecule modality, but its specific mechanism of action is not publicly available from the clinical trial information.

Who makes BIIB015?

BIIB015 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company sponsored the Phase 1 clinical trial of BIIB015 in patients with solid tumors.

What phase is BIIB015 in?

BIIB015 is in Phase 1 clinical development. A Phase 1 study of BIIB015 in relapsed or refractory solid tumors has been completed. The drug is investigational and has not received FDA approval.

What clinical trials is BIIB015 in?

BIIB015 has one completed clinical trial, registered as NCT00674947. This was a Phase 1 study in 55 patients with relapsed or refractory solid tumors, conducted in the United States. The trial was uncontrolled and not randomized or blinded.

Is BIIB015 the same as any other drug?

No alternative names for BIIB015 have been reported. The drug is identified solely by its code name BIIB015 in clinical trial records.